What is Stalicla?
Stalicla operates at the intersection of advanced data analytics and clinical pharmacology. The company has developed a clinically validated neuro-precision platform designed to de-risk the drug development process by identifying specific patient subpopulations that are most likely to respond to targeted therapies. This precision-first approach is particularly vital in the treatment of autism and other neurodevelopmental conditions, where biological heterogeneity has historically hindered therapeutic success.
The company's current portfolio includes STP1, which is approaching Phase 2 clinical trials, and a secondary asset undergoing similar development. Furthermore, the advancement of STP7 (Mavoglurant) toward Phase 3 trials, supported by government-backed funding, highlights the company's ability to secure diverse capital streams to sustain long-term research and development objectives.
How much funding has Stalicla raised?
Stalicla has raised a total of $29.9M across 3 funding rounds:
Series A
$10M
Series B
$17.4M
Other Financing Round
$2.5M
Series A (2018): $10M, investors not publicly disclosed
Series B (2024): $17.4M, investors not publicly disclosed
Other Financing Round (2025): $2.5M supported by Addex Therapeutics
Key Investors in Stalicla
Addex Therapeutics
A Swiss-based clinical-stage pharmaceutical firm specializing in the development of novel orally available small molecule drugs, specifically allosteric modulators for neurological conditions.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Stalicla?
Looking ahead, Stalicla is poised to transition from a research-heavy entity into a late-stage clinical powerhouse. The strategic deployment of the $2.5M will be instrumental in accelerating the Phase 2 trials for its lead assets. As the company moves closer to potential commercialization, the focus will likely shift toward regulatory milestones and the expansion of its precision medicine ecosystem.
The integration of its proprietary platform with upcoming clinical data will be the primary driver of value creation. Investors and industry stakeholders will be closely monitoring the progression of STP7 and the subsequent data readouts from the STP1 program, as these results will serve as a litmus test for the efficacy of the company's stratified patient approach in the broader biopharmaceutical market.
